** Shares of drug developer Alpha Cognition ACOG.O rise 16% to $6.99 premarket

** Co says its Alzheimer’s drug Zunveyl improved cognition, behavior and daily functioning in most patients in a real-world observational study of long-term care residents with the memory‑robbing disease

** 92% of patients showed cognitive improvement after starting the drug, while 93% saw better behavior and mood symptoms like agitation and sleep issues, co says

** Says 80% of patients delayed or stopped other psychiatric drugs such as antipsychotics while on treatment

** Co says drug showed better stomach-related tolerability versus older treatments and helped daily activities and sleep in most patients

** Study reviewed 162 patients but had no control group, meaning results cannot confirm the drug directly caused improvements, co says

** As of last close, stock down ~7% YTD